Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Clarissa G. Barnes, Frederick L. Brancati, MD, MHS, and Tiffany L. Gary, PhD, MHS
To combat the rising incidence of type 2 diabetes, New York City requires laboratories with electronic reporting capacity to upload data on hemoglobin A1c measurements to a city department of health registry.
Eleanor Fleming, PhD, DDS, MPH, Julie Frantsve-Hawley, PhD, and Myechia Minter-Jordan, MD, MBA
Continued separation of dental and oral health from general medical care generates unnecessary prescriptions and pain management that are neither restorative nor responsive to patients’ primary complaints.
AMA J Ethics. 2022;24(1):E48-56. doi:
10.1001/amajethics.2022.48.
Lindsey E. Carlasare joins Ethics Talk to discuss her article, coauthored with Dr Gerald B. Hickson: “Whose Responsibility Is It to Address Bullying in Health Care?”